Ticker Details
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
IPO Date:	September 7, 2005
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.71B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.53 | 2.21%
Avg Daily Range (30 D):	$5.34 | 1.80%
Avg Daily Range (90 D):	$4.64 | 1.75%

Institutional Daily Volume
Avg Daily Volume:	.31M
Avg Daily Volume (30 D):	.18M
Avg Daily Volume (90 D):	.21M

Trade Size
Avg Trade Size (Sh.):	99
Avg Trade Size (Sh.) (30 D):	27
Avg Trade Size (Sh.) (90 D):	31

Institutional Trades
Total Institutional Trades:	5,849
Avg Institutional Trade:	$3.4M
Avg Institutional Trade (30 D):	$6.93M
Avg Institutional Trade (90 D):	$7.9M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.55M
Avg Closing Trade (30 D):	$8.99M
Avg Closing Trade (90 D):	$10.56M
Avg Closing Volume:	30.09K

News

Jul 13, 2026 @ 4:40 PM 3 Overlooked Stocks Positioned for the Next Market... Source: Bridget Bennett

Jul 6, 2026 @ 11:35 AM CRISPR Therapeutics vs. Viking Therapeutics: Which... Source: Erin Kennedy

Jun 12, 2026 @ 8:05 PM XOMA Royalty Corporation Declares Quarterly Prefer... Source: Globe Newswire

Jun 10, 2026 @ 11:00 AM Ligand Announces 2026 Investor Day in New York Cit... Source: Na

Jun 7, 2026 @ 12:28 PM A Ligand Pharmaceuticals (LGND) Insider Sold 5,000... Source: Cory Renauer

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$10.07	$2.42	$-.67
Diluted EPS	$9.41	$2.22	$-.67
Revenue	$290.54M	$63.69M	$51.72M
Gross Profit
Net Income / Loss	$197.22M	$48.51M	$-13.35M
Operating Income / Loss	$94.73M	$8.59M	$17.37M
Cost of Revenue
Net Cash Flow	$936.22M	$891.61M	$-59.83M
PE Ratio

Splits
Nov 19, 2010	1:6